156 related articles for article (PubMed ID: 37624393)
1. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
He S; Shao Q; Zhao J; Bian J; Zhao Y; Hao X; Li Y; Hu L; Liu B; He H; Huang L; Jiang Q
Cancer Chemother Pharmacol; 2023 Nov; 92(5):399-410. PubMed ID: 37624393
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia.
Wang Q; Jiang ZP; Yu EQ; Zeng J; Zhu Y; Cai HL; Yan M; Xiang DX; Zhao XL; Xu P; Jiao Z; Banh HL
Pharmacogenomics; 2019 Mar; 20(4):251-260. PubMed ID: 30767712
[TBL] [Abstract][Full Text] [Related]
3. Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.
Shriyan B; Mehta P; Patil A; Jadhav S; Kumar S; Puri AS; Govalkar R; Krishnamurthy MN; Punatar S; Gokarn A; Khattry N; Gota V
Eur J Clin Pharmacol; 2022 Aug; 78(8):1321-1330. PubMed ID: 35652931
[TBL] [Abstract][Full Text] [Related]
4. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Singh O; Chan JY; Lin K; Heng CC; Chowbay B
PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.
Adeagbo BA; Olugbade TA; Durosinmi MA; Bolarinwa RA; Ogungbenro K; Bolaji OO
J Clin Pharmacol; 2017 Dec; 57(12):1554-1563. PubMed ID: 28618035
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia.
He S; Zhao J; Bian J; Zhao Y; Li Y; Guo N; Hu L; Liu B; Shao Q; He H; Huang L; Jiang Q
Pharm Res; 2023 Oct; 40(10):2413-2422. PubMed ID: 37726405
[TBL] [Abstract][Full Text] [Related]
8. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
[TBL] [Abstract][Full Text] [Related]
10. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
11. Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Salimizand H; Amini S; Abdi M; Ghaderi B; Azadi NA
Tumour Biol; 2016 Jan; 37(1):791-8. PubMed ID: 26250462
[TBL] [Abstract][Full Text] [Related]
12. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
[TBL] [Abstract][Full Text] [Related]
13. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G
Haematologica; 2013 Feb; 98(2):193-200. PubMed ID: 22875622
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population.
Ansari M; Kalantary-Khandani B; Pardakhty A; Safavi M; Mosavi N; Mohajeri E
Gulf J Oncolog; 2016 Sep; 1(22):26-36. PubMed ID: 28191803
[TBL] [Abstract][Full Text] [Related]
15. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
Wang Y; Zhou L; Dutreix C; Leroy E; Yin Q; Sethuraman V; Riviere GJ; Yin OQ; Schran H; Shen ZX
Br J Clin Pharmacol; 2008 Jun; 65(6):885-92. PubMed ID: 18384443
[TBL] [Abstract][Full Text] [Related]
16. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
18. Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
Galeotti L; Ceccherini F; Domingo D; Laurino M; Polillo M; Di Paolo A; Baratè C; Fava C; D'Avolio A; Cervetti G; Guerrini F; Fontanelli G; Ciabatti E; Grassi S; Arrigoni E; Danesi R; Petrini M; Cornolti F; Saglio G; Galimberti S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):767-773. PubMed ID: 28289867
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
